机构：[1]Department of Medical Oncology, Cancer Hospital Chinese Academy of MedicalSciences and Peking Union Medical College, Beijing, China[2]Department of BreastDisease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of ZhengzhouUniversity & Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[3]Department of Oncology, TheFirst Hospital of Jilin University, Changchun, China[4]Breast Internal MedicineDepartment, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya Schoolof Medicine, Central South University, Changsha, China[5]Department of BreastOncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China[6]Department of Breast Internal Medicine, The First Hospital of China Medical University,Shenyang, Liaoning, China[7]Department of Internal Medicine, Sun Yat-senUniversity Cancer Center, Guangzhou, China[8]Breast Surgery, Shandong Cancer Hospital& Institute, Jinan, China[9]Breast Center, The Fourth Hospital of Hebei MedicalUniversity and Hebei Tumor Hospital, Shijiazhuang, China河北医科大学第四医院[10]Department of MedicalOncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[11]Medical Oncology, The First Affiliated Hospital of Guangxi Medical University,Nanning, China[12]Medical Oncology Department, Cancer Hospital Harbin MedicalUniversity, Harbin, China[13]Breast Tumor Center, Sun Yat-sen Memorial Hospital, SunYat-sen University, Guangzhou, China中山大学附属第二医院[14]Breast Cancer Center, Affiliated Cancer Hospitalof Chongqing University, Chongqing, China[15]Breast Internal Medicine Department,Liaoning Cancer Hospital & Institute, Shenyang, China[16]Breast Surgery,Guangxi Medical University Affiliated Tumor Hospital, Nanning, China[17]Departmentof Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China
第一作者机构：[1]Department of Medical Oncology, Cancer Hospital Chinese Academy of MedicalSciences and Peking Union Medical College, Beijing, China
推荐引用方式(GB/T 7714)：
B. Xu,M. Yan,F. Ma,et al.Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial[J].ANNALS OF ONCOLOGY.2022,33(7):S1387-S1387.doi:10.1016/j.annonc.2022.08.014.
APA：
B. Xu,M. Yan,F. Ma,W. Li,Q. Ouyang...&X. Zhu.(2022).Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial.ANNALS OF ONCOLOGY,33,(7)
MLA：
B. Xu,et al."Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial".ANNALS OF ONCOLOGY 33..7(2022):S1387-S1387
医学